Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study

30 Apr 2014

Abstract excerpt

BACKGROUND: Friedreich's ataxia is a progressive degenerative disorder caused by deficiency of the frataxin protein. Expanded GAA repeats within intron 1 of the frataxin (FXN) gene lead to its heterochromatinisation and transcriptional silencing. Preclinical studies have shown that the histone deacetylase inhibitor nicotinamide (vitamin B3) can remodel the pathological heterochromatin and upregulate expression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis Research
Share to Genetic Neurodegenerative Diseases
Share to Sirtuins and Resveratrol in Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24794816
DOI: 10.1016/s0140-6736(14)60382-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation studyPMID 24794816Read ↗

Translating HDAC inhibitors in Friedreich’s ataxiaSemantic proximity Read ↗

Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxiaSemantic proximity Read ↗

Epigenetic therapy for <scp>F</scp> riedreich ataxiaSemantic proximity Read ↗

Two New Pimelic Diphenylamide HDAC Inhibitors Induce Sustained Frataxin Upregulation in Cells from Friedreich's Ataxia Patients and in a Mouse ModelSemantic proximity Read ↗

Investigation into the silencing of heterochromatin in mammalian cellsSemantic proximity Read ↗

Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model.Semantic proximity Read ↗

Advances in Gene and Cellular Therapy in Friedreich Ataxia.Semantic proximity Read ↗

<i>FXN</i> methylation predicts expression and clinical outcome in Friedreich ataxiaSemantic proximity Read ↗

Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.Semantic proximity Read ↗

From Genetic Mutation to Therapy in Friedreich Ataxia: Molecular Mechanisms, Therapeutic Advances, and Translational ChallengesSemantic proximity Read ↗

The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues.Semantic proximity Read ↗

A new FRDA mouse model [Fxnnull:YG8s(GAA) > 800] with more than 800 GAA repeatsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.